Billiontoone Inc's Business Segments

BillionToOne, Inc. is a molecular diagnostics company specializing in single molecule next-generation sequencing (smNGS) technology for detecting and quantifying genetic targets with single-molecule sensitivity. The company's patented Quantitative Counting Templates (QCTs) enable measurements at the physical limit of detection, addressing challenges in identifying sparse disease signals in cell-free DNA (cfDNA). BillionToOne has developed prenatal and oncology diagnostic products, including UNITY, launched in 2019 as the first non-invasive prenatal test (NIPT) assessing fetal risk for recessive conditions without requiring paternal samples or invasive procedures. In 2023, the company introduced Northstar Select and Northstar Response, pan-cancer liquid biopsy tests designed to detect actionable mutations and quantify tumor burden at the single molecule level. BillionToOne's operations focus on advancing technology platforms, delivering precise diagnostic products, scaling growth efficiently, and progressing toward profitability. The company aims to overcome limitations of traditional next-generation sequencing technologies in detecting cfDNA, facilitating real-time disease diagnosis and monitoring.

The company operates as a single operating and reportable segment. The Chief Executive Officer, serving as the Chief Operating Decision Maker (CODM), reviews company-wide financial information to allocate resources and evaluate performance. Key financial metrics considered include cash used in operations, revenue, gross margin, and net income (loss), with net income (loss) serving as the segment's measure of profitability. The company's revenues are derived from prenatal and oncology testing services provided to patients, utilizing its proprietary molecular diagnostic technology platform. The majority of the company's customers and long-lived assets are located in the United States. The technology platform is applied consistently across both prenatal and oncology testing services.